2.9001
1.02%
-0.0299
After Hours:
2.9001
MEI Pharma Inc stock is currently priced at $2.9001, with a 24-hour trading volume of 4,231.
It has seen a -1.02% decreased in the last 24 hours and a -8.22% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.91 pivot point. If it approaches the $2.85 support level, significant changes may occur.
Previous Close:
$2.93
Open:
$2.875
24h Volume:
4,231
Market Cap:
$19.32M
Revenue:
$105.38M
Net Income/Loss:
$19.84M
P/E Ratio:
-0.6264
EPS:
-4.63
Net Cash Flow:
$-53.02M
1W Performance:
+1.05%
1M Performance:
-8.22%
6M Performance:
-55.79%
1Y Performance:
-60.00%
MEI Pharma Inc Stock (MEIP) Company Profile
Name
MEI Pharma Inc
Sector
Industry
Phone
858 369 7100
Address
11455 El Camino Real, San Diego, CA
MEI Pharma Inc Stock (MEIP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-25-22 | Downgrade | Jefferies | Buy → Hold |
Mar-25-22 | Downgrade | Stifel | Buy → Hold |
Mar-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Feb-03-22 | Initiated | Jefferies | Buy |
Sep-22-20 | Initiated | Alliance Global Partners | Buy |
May-29-20 | Initiated | SunTrust | Buy |
Dec-20-18 | Initiated | H.C. Wainwright | Buy |
Jul-27-18 | Upgrade | Stifel | Hold → Buy |
Jul-13-18 | Initiated | SunTrust | Buy |
Apr-18-16 | Reiterated | Wedbush | Neutral |
Mar-23-15 | Downgrade | ROTH Capital | Buy → Neutral |
Dec-18-14 | Reiterated | ROTH Capital | Buy |
Oct-16-14 | Reiterated | ROTH Capital | Buy |
Jul-08-14 | Resumed | Brean Capital | Buy |
Oct-22-13 | Reiterated | Stifel | Buy |
Apr-15-13 | Initiated | Stifel | Buy |
View All
MEI Pharma Inc Stock (MEIP) Latest News
StockNews.com Initiates Coverage on SuperCom (NASDAQ:SPCB) - Defense World
Defense World
SeaStar Medical (NASDAQ:ICU) Shares Set to Reverse Split on Monday, June 10th - Defense World
Defense World
Goldman Sachs Future Planet Equity ETF (NYSEARCA:GSFP) Shares Down 1.5% - Defense World
Defense World
Independence Contract Drilling (NYSE:ICD) Now Covered by Analysts at StockNews.com - Defense World
Defense World
Nvidia Just Announced a Stock Split. History Says This Is What Happens Next. - The Globe and Mail
The Globe and Mail
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia
Yahoo Lifestyle Australia
MEI Pharma Inc Stock (MEIP) Financials Data
MEI Pharma Inc (MEIP) Revenue 2024
MEIP reported a revenue (TTM) of $105.38 million for the quarter ending September 30, 2023, a +152.90% rise year-over-year.
MEI Pharma Inc (MEIP) Net Income 2024
MEIP net income (TTM) was $19.84 million for the quarter ending December 31, 2023, a +163.69% increase year-over-year.
MEI Pharma Inc (MEIP) Cash Flow 2024
MEIP recorded a free cash flow (TTM) of -$53.02 million for the quarter ending December 31, 2023, a +14.39% increase year-over-year.
MEI Pharma Inc (MEIP) Earnings per Share 2024
MEIP earnings per share (TTM) was $2.97 for the quarter ending December 31, 2023, a +163.19% growth year-over-year.
About MEI Pharma Inc
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):